**Supplementary Table S2. Baseline characteristics of the patients included (*PIK3CA* cohort) or not (no-*PIK3CA* cohort) in the *PIK3CA* analysis.**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Characteristics** |  |  | ***PIK3CA* cohort** | **No-*PIK3CA***  **cohort** | **All randomized** | ***P* value** |
|  |  |  | ***N* (%)** | ***N* (%)** | ***N* (%)** |  |
|  | Randomized |  | 803 (64%) | 450 (36%) | 1253 (100) |  |
| Age (years) |  |  |  |  |  |  |
|  | <60 |  | 497 (62) | 305 (68) | 802 (64) |  |
|  | ≥60 |  | 306 (38) | 145 (32) | 451 (36) | 0.037 |
|  | Median (Q1-Q3) |  | 56 (48-64) | 54 (46-62) | 55 (48-64) | 0.012 |
| Menopausal status |  |  |  |  |  |  |
| Premenopausal |  | 276 (34) | 172 (38) | 448 (36) |  |
| Postmenopausal |  | 526 (66) | 276 (62) | 802 (64) | 0.160 |
| AJCC Stage |  |  |  |  |  |  |
|  | I |  | 329 (41) | 180 (40) | 509 (41) |  |
|  | II |  | 354 (44) | 195 (44) | 549 (44) |  |
|  | III |  | 118 (15) | 73 (16) | 191 (15) | 0.762 |
| N stage |  |  |  |  |  |  |
|  | N0  N1-N2  N3 |  | 428 (53)  252 (31)  123 (15) | 244 (54)  131 (29)  75 (17) | 672 (54)  383 (30)  198 (16) | 0.640 |
| Hormone receptors |  |  |  |  |  |  |
|  | Negative |  | 236 (29) | 164 (36) | 400 (32) |  |
|  | Positive |  | 567 (71) | 286 (64) | 853 (68) | 0.010 |
| Histological grade |  |  |  |  |  |  |
|  | Grade 1- 2 |  | 226 (28) | 148 (34) | 374 (30) |  |
|  | Grade 3 |  | 566 (72) | 292 (66) | 858 (70) | 0.062 |
| TILs | Median (Q1-Q3) |  | 5 (1-15) | 5 (1-30) | 5 (1-15) | 0.040 |

Abbreviations: TILs, tumor infiltrating lymphocytes; AJCC, American Joint Committee on Cancer